Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GE HealthCare Technologies (GEHC) Research & Development (2022 - 2025)

GE HealthCare Technologies (GEHC) has disclosed Research & Development for 4 consecutive years, with $323.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 6.1% year-over-year to $323.0 million, compared with a TTM value of $1.3 billion through Dec 2025, down 3.89%, and an annual FY2025 reading of $1.3 billion, down 3.89% over the prior year.
  • Research & Development was $323.0 million for Q4 2025 at GE HealthCare Technologies, up from $291.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $344.0 million in Q4 2024 and bottomed at $238.0 million in Q1 2022.
  • Average Research & Development over 4 years is $300.1 million, with a median of $308.5 million recorded in 2023.
  • The sharpest move saw Research & Development increased 23.85% in 2023, then decreased 7.91% in 2025.
  • Year by year, Research & Development stood at $271.0 million in 2022, then grew by 16.24% to $315.0 million in 2023, then grew by 9.21% to $344.0 million in 2024, then fell by 6.1% to $323.0 million in 2025.
  • Business Quant data shows Research & Development for GEHC at $323.0 million in Q4 2025, $291.0 million in Q3 2025, and $302.0 million in Q2 2025.